“…Firstly, these viruses are naturally S-phase dependent, so that they preferentially target host cell populations that are proliferating, while sparing those that are not. The rodent parvoviruses are also markedly oncoselective, displaying enhanced fitness and toxicity in many human cancer cell lines compared to their untransformed counterparts, although they show variable tropism between tumor types (Chen et al, 1986; Chen et al, 1989; Cornelis et al, 2004; Dupont et al, 2000; Guetta et al, 1990; Legrand et al, 1992; Mousset et al, 1994; Rommelaere and Cornelis, 1991; Van Hille et al, 1989). They show potent oncosuppressive properties in many in vivo models, including syngeneic mouse tumor models and human xenografts transplanted into immunocompromised animals (Dupressoir et al, 1989; Faisst et al, 1998; Raykov et al, 2007; Rommelaere and Cornelis, 1991; Shi et al, 1997; Toolan, 1967; Toolan et al, 1982), and can also induce both curative and protective immune responses in some immunocompetent rodent tumor models (Guetta et al, 1986; Geletneky et al, 2010).…”